TITLE

A Comparison of Itraconazole Versus Fluconazole as Maintenance Therapy for AIDS-Associated Cryptococcal Meningitis

AUTHOR(S)
Saag, Michael S.; Cloud, Gretchen A.; Graybill, J. Richard; Sobel, Jack D.; Tuazon, Carmelita U.; Johnson, Philip C.; Fessel, W. Jeffrey; Moskovitz, Bruce L.; Wiesinger, Barbara; Cosmatos, Dennis; Riser, Laura; Thomas, Carolynn; Hafner, Richard; Dismukes, William E.
PUB. DATE
February 1999
SOURCE
Clinical Infectious Diseases;2/1/1999, Vol. 28 Issue 2, p291
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study was designed to compare the effectiveness of fluconazole vs. itraconazole as mainte-nance therapy for AIDS-associated cryptococcal meningitis. HIV-infected patients who had been successfully treated (achieved negative culture of CSF) for a first episode of cryptococcal meningitis were randomized to receive fluconazole or itraconazole, both at 200 mg/d, for 12 months. The study was stopped prematurely on the recommendation of an independent Data Safety and Monitoring Board. At the time, 13 (23%) of 57 itraconazole recipients had experienced culture-positive relapse, compared with 2 relapses (4%) noted among 51 fluconazole recipients (P = .006). The factor best associated with relapse was the patient having not received flucytosine during the initial 2 weeks of primary treatment for cryptococcal disease (relative risk = 5.88; 95% confidence interval, 1.27-27.14; P = .04). Fluconazole remains the treatment of choice for maintenance therapy for AIDS-associated cryptococcal disease. Flucytosine may contribute to the prevention of relapse if used during the first 2 weeks of primary therapy.
ACCESSION #
6235456

 

Related Articles

  • Treatment of Gram--Negative Bacillary Meningitis in Adults. Rahal Jr., James J. // Annals of Internal Medicine;Aug72, Vol. 77 Issue 2, p295 

    Provides information on the treatment of Gram-negative bacillary meningitis, associated with the central nervous system. Application of antimicrobial therapy in Gram-negative activity; Utilization of kanamycin and gentamicin as treatment for the condition; Effect of antibiotics on the central...

  • Issues in the management of bacterial meningitis. Tunkel, Allan R.; Scheld, W. Michael // American Family Physician;10/1/1997, Vol. 56 Issue 5, p1355 

    Presents information on acute bacterial meningitis. Antimicrobial therapies for the disease; Clinical features of patients with acute bacterial meningitis; Diagnostic evaluation of patients with the disease; Initial approach to the management of the disease.

  • Corticosteroids for Everyone with Meningitis? Tunkel, Allan R.; Scheld, W. Michael // New England Journal of Medicine;11/14/2002, Vol. 347 Issue 20, p1613 

    Discusses the treatment of pneumococcal meningitis with adjunctive dexamethasone therapy. Statement the dexamethasone will work only if the disease was caused by streptococcus pneumoniae; How dexamethasone therapy should be administered prior to the first dose of an antimicrobial agent.

  • Evaluating treatment program options.  // High Plains Journal;10/8/2012, Vol. 130 Issue 41, p13-B 

    The article offers information on the aspects of older class of anti-microbial treatment options and post-treatment interval period.

  • Bioinformatics and the Discovery of Novel Anti-Microbial Targets. Volker, Craig; Brown, James R. // Current Drug Targets - Infectious Disorders;Dec2002, Vol. 2 Issue 4, p279 

    Genomic research is playing a critical role in the discovery of new antimicrobial drugs. The rapid increase in bacterial and eukaryotic genome sequences allows for new and innovative ways for obtaining antimicrobial protein targets. Here, we describe a two level strategy for target...

  • MRSA's SILVER BULLET. Rubinger, Jack // Executive Housekeeping Today;May2007, Vol. 29 Issue 5, p24 

    The article provides information on the silver antimicrobial gel, an effective fighting agent that can stop Methicillin-resistant Staphylococcus aureaus (MRSA) infection in the U.S. Accordingly, the Centers for Disease Control estimates that more than 130,000 people in the country are...

  • Determining the cost of antimicrobial therapy: A focus on fluoroquinolones. Goff, Debra A. // Formulary;Jul98, Vol. 33 Issue 7, p648 

    Discusses factors affecting the cost of antimicrobial therapy. Classifications of antimicrobial activity; Administration costs; Monitoring costs; Costs associated with side effects; Efficacy; Patient satisfaction; Effect of the characteristics of quinolones on the cost associated with the factors.

  • How to create a therapeutics committee that is scientifically and economically sound. Quintiliani, Richard; Quercia, Robert A. // Formulary;Oct2003, Vol. 38 Issue 10, p594 

    Focuses on how to manage the various challenges facing therapeutic committees. Search for ways to balance science and economics, with particular attention to anti-infective agents; Adoption of conversion policies; Evaluation of information; Establishment of priorities.

  • The Impact of Antimicrobial Resistance on Health and Economic Outcomes. Cosgrove, Sara E.; Carmeli, Yehuda // Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1433 

    Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics